Anti-human Amyloid-beta E22P (11A1) Mouse IgG
- Quantity / Tests
- 50 µg
- Species / Antigen
- Synthetic peptide of E22P- Amyloidβ10-35 part
- Host
- Mouse
- Subclass / Clone
- IgG1/11A1
- Type
- Monoclonal
- Purification
- Protein A
- Regulatory Status
- RUO
Alzheimer’s disease (AD) is characterized by the presence of extracellular plaques and intracellular neurofibrillary tangles (NFTs) in the brain. Aggregation of the amyloid β-protein, especially the Aβ42 isoform, plays a critical role in the pathogenesis of AD. Shirasawa and Irie et. al have proposed a toxic conformer with a turn at positions 22 and 23, as well as a nontoxic conformer with a turn at positions 25 and 26, in Aβ42 aggregates from systematic proline scanning and solid-state NMR studies. This monoclonal antibody named 11A1 was developed for toxic Aβ42, using E22P-Aβ10-35, a minimum moiety for neurotoxicity containing the turn at positions 22 and 23, for the generation. Immunohistochemical studies showed that not only extracellular but intracellular amyloid was stained in human AD brains, which suggest that 11A1 could detect toxic oligomers of Aβ with the turn at positions 22 and 23.
Our Product Families
Our comprehensive immunoassay portfolio includes a number of specialty diagnostic immunoassays for endocrinology, immunology and autoimmunity, as well as for diagnosis of multiple infectious diseases. We are pioneers and market leaders in saliva diagnostics, with over 40 years of experience supplying a broad portfolio of luminescence- and ELISA-based tests, including our highly acclaimed HMGB1 and MuSK-Ab ELISAs.
And as experts in laboratory automation, we can support our customers with the protocols for open ELISA platforms, such as the Freedom EVOlyzer or Thunderbolt®.
All products are only available for sale to laboratory professionals and may not be available in all countries. Availability and regulatory status may vary across regions depending on local country-specific registration. Please always read and follow the instructions for use.
All of our assays have been designed and manufactured to meet the highest global regulatory requirements and quality standards. Tecan is certified under ISO 9001:2015, ISO 13485:2016 and is audited by a notified body according to Medical Device Single Audit Program (MDSAP).
This is who we are.
As part of the Tecan Group, we have a leading market position in diagnostics and research, with over 40 years of experience in the development, manufacture and supply of enzyme-, radiolabel- and luminescence-based immunoassays.
Our range of high-quality immunoassays is supported by a diverse portfolio of automated solutions, making us the perfect partner for you and your customers.
Happy to help.
At Tecan, we are driven to improve people’s lives and health.